| 000 | 02298cam a2200229 4500500 | ||
|---|---|---|---|
| 005 | 20250119115539.0 | ||
| 041 | _afre | ||
| 042 | _adc | ||
| 100 | 1 | 0 |
_aJroundi, Chaymae _eauthor |
| 700 | 1 | 0 |
_a Baybay, Hanane _eauthor |
| 700 | 1 | 0 |
_a Kassel, Jihad _eauthor |
| 700 | 1 | 0 |
_a Douhi, Zakia _eauthor |
| 700 | 1 | 0 |
_a Soughi, Meryem _eauthor |
| 700 | 1 | 0 |
_a Elloudi, Sara _eauthor |
| 700 | 1 | 0 |
_a Mernissi, Fatima-Zahra _eauthor |
| 245 | 0 | 0 | _aNd:YAG Lasers and recalcitrant warts: A series of 28 cases |
| 260 | _c2024. | ||
| 500 | _a42 | ||
| 520 | _aBackground: Warts are benign epithelial growths caused by HPV (human papillomavirus). Some lesions may be more difficult to treat due to their location and size. The objective of our study was to evaluate the efficacy and safety of Nd:YAG lasers in the treatment of recalcitrant warts. Materials and methods: A prospective study was conducted in the dermatology department of the Hassan II University Hospital in Fez. Over a 4-year period from 2017 to 2021, 28 patients with recalcitrant warts were treated with an Nd:YAG laser. The parameters used were a spot size of 3–5 mm, a pulse duration of 20 ms, and a fluence of 150–240 J/cm2, performed under local anesthesia. The final result was achieved in all our patients, with immediate post-laser dermoscopic examinations implemented to minimize the number of sessions required. Results: The average age of our patients was 31 years. The locations treated were the face, palms, soles of the feet, and periungual areas. The number of sessions ranged from 1 and 3, with myrmecia and lesions larger than 1 cm requiring additional sessions. Observed side effects include hemorrhagic bullae after the session, which were resolved with local wound care. One case of nail dystrophy was noted in a child. The complete remission rate was 92.85% (26 out of 28). During a median follow-up period of 25 months, 3 recurrences were observed. Conclusion: We recommend the Nd:YAG laser as a safe and effective option for the removal or reduction of resistant and profuse warts. | ||
| 786 | 0 | _nCahiers Santé Médecine Thérapeutique | 33 | 3 | 2024-10-08 | p. 117-121 | 2780-8858 | |
| 856 | 4 | 1 | _uhttps://shs.cairn.info/journal-cahiers-sante-medecine-therapeutique-2024-3-page-117?lang=en&redirect-ssocas=7080 |
| 999 |
_c416377 _d416377 |
||